Volver al portal Europarl

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (selección)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Este documento no está disponible en su lengua y se le ofrece en una de las lenguas que están disponibles en la barra de lenguas.

Parliamentary questions
1 March 2017
P-001382-17
Question for written answer
to the Commission
Rule 130
Alexander Graf Lambsdorff (ALDE)

 Subject:  Pharmaceutical law in Poland
 Answer(s) 

On 9 April 2015, the Polish Parliament passed an act amending and supplementing the Pharmaceutical Act. The act was published in the Polish Official Journal on 11 June and entered into force on 12 July 2015(1). Under this law, 187 products are banned from export, thereby affecting intra-EU trade. Article 35 of the Treaty on the Functioning of the European Union prohibits Member States from applying quantitative restrictions on exports and measures having equivalent effect.

Is the Commission aware of these measures related to the export to other Member States of medicinal products for human use?

Does it intend to launch an infringement procedure in the form of a reasoned opinion?

What is the difference between this and similar cases in Slovakia and Portugal?

(1) Act on amending the Act — Pharmaceutical Law and Certain Other Acts; Publication in Journal of Laws 2015, Item 788 (Dz.U.2015.788).

Última actualización: 7 de marzo de 2017Aviso jurídico